The Discovery of Dual IGF-1R and IR Inhibitor FQIT for the Treatment of Cancer

Case Studies in Modern Drug Discovery and Development

Volumn , Issue , 2012, Pages 127-153

  Jin, Meizhong ^a   Buck, Elizabeth ^a   Mulvihill, Mark J ^a  

^a OSI PHARMACEUTICALS INC   (United States)

Author keywords

FQIT and bioisosteric core replacement; IGF 1R IR pathway, targeting in anti cancer therapy; IR inhibitor FQIT of dual IGF 1R, in cancer; OSI 906 backup program and dual IGF 1R IR inhibitor FQIT discovery; OSI 906 discovery, targeting IGF 1R and IR kinase activities

Indexed keywords

EID: 84887160552     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118219683.ch7     Document Type: Chapter

References (42)

1. KAISER, U., SCHARDT, C., BRANDSCHEIDT, D.,WOLLMER, E., and HAVEMANN, K. Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer. J. Cancer Res. Clin. Oncol. 1993, 119, 665-668.
2. KONDO, M., SUZUKI, H., UEDA, R., OSADA, H., TAKAGI, K., TAKAHASHI, T., and TAKAHASHI, T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 1995, 10, 1193-1198.
3. RUBIN, R. and BASERGA, R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab. Invest. 1995, 73, 311-331.
4. SELL, C., RUBINI, M., RUBIN, R., LIU, J. P., EFSTRATIADIS, A., and BASERGA, R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. 1993, 90(23),11217-11221.
5. LEROITH, D. and ROBERTS, C. T. JR., The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195, 127-137.
6. MA, J.,GIOVANNUCCI, E., POLLAK, M., LEAVITT, A., TAO, Y., GAZIANO, J. M., and STAMPFER, M. J. A prospective study of plasma C-peptide and colorectal cancer risk in men. J. Natl. Cancer Inst. 2004, 96, 546-553.
7. POLLAK, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 2008, 8, 915-928.
8. JEROME, L., ALAMI, N., BELANGER, S., PAGE, V., YU, Q., PATERSON, J., SHIRY, L., PEGRAM, M., and LEYLAND-JONES, B. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 2006, 66, 7245-7252.
9. LU, Y., ZI, X., and POLLAK, M. Molecular mechanisms underlying IGF-I-induced attenuation of the growthinhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 2004, 108, 334-341.
10. LU, Y., ZI, X., ZHAO, Y., MASCARENHAS, D., and POLLAK, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93, 1852-1857.
11. CHAKRAVARTI, A., LOEFFLER, J. S., and DYSON, N. J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002, 62, 200-207.
12. GOOCH, J. L., VAN DEN BERG C. L., and YEE, D. Insulinlike growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects. Breast Cancer Res. Treatment 1999, 56, 1-10.
13. JONES, H. E., GODDARD, L., GEE, J. M., HISCOX, S., RUBINI, M., BARROW, D., KNOWLDEN, J. M., WILLIAMS, S., WAKELING, A. E., and NICHOLSON, R. I. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839, Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 2004, 11, 793-814.
14. KNOWLDEN, J. M., HUTCHESON, I. R., BARROW, D., GEE, J. M., and NICHOLSON, R. I. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005, 146, 4609-4618.
15. LU, Y., ZI, X., ZHAO, Y., MASCARENHAS, D., and POLLAK, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93, 1852-1857.
16. NAHTA, R., YUAN, L. X., ZHANG, B., KOBAYASHI, R., and ESTEVA, F. J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65, 11118-11128.
17. TURNER, B. C., HAFFTY, B. G., NARAYANAN, L., YUAN, J., HAVRE, P. A., GUMBS, A. A., KAPLAN, L., BURGAUD, J. L., CARTER, D., BASERGA, R., and GLAZER, P. M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997, 57, 3079-3083.
18. GIORGINO, F., BELFIORE, A.,MILAZZO, G., COSTANTINO, A., MADDUX, B.,WHITTAKER, J., GOLDFINE, I. D., and VIGNERI, R. Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol. Endocrinol. 1991, 5, 452-459.
19. BUCK, E., GOKHALE, P. C., KOUJAK, S., BROWN, E., EYZAGUIRRE, A., TAO, N., ROSENFELD-FRANKLIN, M., LERNER, L., CHIU, M., WILD, R., EPSTEIN, D., PACHTER, J. A., and MIGLARESE, M. R. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010 9, 2652-2664.
20. HEUSON, J. C. and LEGROS, N. Effect of insulin and of alloxan diabetes on growth of the rat mammary carcinoma in vivo. Eur. J. Cancer 1970, 6, 349-351.
21. HEUSON, J. C. and LEGROS, N. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res. 1972, 32, 226-232.
22. HEUSON, J. C., LEGROS, N., and HEIMANN, R. Influence of insulin administration on growth of the 7,12- dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res. 1972, 32, 233-238.
23. SCIACCA, L., COSTANTINO, A., PANDINI, G., MINEO, R., FRASCA, F., SCALIA, P., SBRACCIA, P., GOLDFINE, I. D., VIGNERI, R., and BELFIORE A. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18, 2471-2479.
24. VELLA, V., PANDINI, G., SCIACCA, L., MINEO, R., VIGNERI, R., PEZZINO, V., and BELFIORE, A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J. Clin. Endocrinol. Metab. 2002, 87, 245-254.
25. COX, M. E., GLEAVE, M. E., ZAKIKHANI, M., BELL, R. H., PIURA, E., VICKERS, E., CUNNINGHAM, M., LARSSON, O., FAZLI, L., and POLLAK, M. Insulin receptor expression by human prostate cancers. Prostate 2009, 69, 33-40.
26. POLLAK, M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr. Opin. Pharmacol. 2008, 8, 384-392.
27. KLING, J. Inhaled insulin's last gasp? Nat. Biotechnol. 2008, 26, 479-480.
28. ENTINGH-PEARSALL, A. and KAHN, C. R. Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J. Biol. Chem. 2004, 279, 38016-38024.
29. FULZELE, K., DIGIROLAMO, D. J., LIU, Z., XU, J., MESSINA, J. L., and CLEMENS, T. L. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 2007, 282, 25649-25658.
30. MULVIHILL, M., JI, Q., COATE, H., COOKE, A., DONG, H., FENG, L., FOREMAN, K., ROSENFELD-FRANKLIN, M., HONDA, A., MAK, G., MULVIHILL, K., NIGRO, A., O'CONNOR, M., PIRRIT, C., STEINIG, A., SIU, K., STOLZ, K., SUN, Y., TAVARES, P., YAO Y., and GIBSON, N. Novel 2- phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Bioorg. Med. Chem. 2008, 16, 1359-1375. AQIP: cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2- phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine.
31. JI, Q., MULVIHILL, M., ROSENFELD-FRANKLIN, M., COOKE, A., FENG, L.,MAK, G., O'CONNOR, M.,YAO,Y., PIRRITT, C., BUCK, E., EYZAGUIRRE, A., ARNOLD, L., GIBSON, N., and PACHTER, J. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulinlike growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol. Cancer Ther. 2007, 6, 2158-2167. PQIP: cis-3-[3-(4-methyl-piperazin-l-yl)- cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a] pyrazin-8-ylamine.
32. MULVIHILL, M., COOKE, A., ROSENFELD-FRANKLIN, M., BUCK, E., FOREMAN, K., LANDFAIR, D., O'CONNOR, M., PIRRIT, C., SUN,Y.,YAO,Y.,ARNOLD, L.,GIBSON, N., and JI, Q. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. FutureMed. Chem. 2009, 1, 1153-1171.
33. CREW, A.P., BHAGWAT, S.V., DONG, H., BITTNER, M.A., CHAN, A., CHEN, X., COATE, H., COOKE, A., GOKHALE, P., HONDA, A., JIN, M., KAHLER, J., MANTIS, C., MULVIHILL, M.J., TAVARES-GRECO, P.A., VOLK, B.,WANG, J.,WERNER, D.S., ARNOLD, L.D., PACHTER, J.A.,WILD, R., and GIBSON, N.W. Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2, Bioorg. Med. Chem. Lett. 2011, 21, 2092-2097.
34. WANG, J., MCCUBBIN, J., JIN, M., LAUFER, R., MAO, Y., CREW, A., MULVIHILL, M., and SNIECKUS, V. Palladiumcatalyzed direct heck aArylation of dual p-deficient/pexcessive heteroaromatics, synthesis of C-5 arylated imidazo[1,5-a]pyrazines. Org. Lett. 2008, 10, 2923-2926.
35. BOARD, J., WANG, J., CREW, A., JIN, M., FOREMAN, K., MULVIHILL, M., and SNIECKUS, V. Synthesis of substituted imidazo[1,5-a]pyrazines via mono-, di-, and directed remote metalation strategies. Org. Lett. 2009, 11, 5118-5121.
36. JIN, M., GOKHALE, P., COOKE, A., FOREMAN, K., BUCK, E., MAY, E., FENG, L., BITTNER, M., KADALBAJOO, M., LANDFAIR, D., SIU, K., STOLZ, K., WERNER, D., LAUFER, R., LI, A., DONG, H., STEINIG, A., KLEINBERG, A., YAO, Y., PACHTER, J.,WILD, R., and MULVIHILL, M. J. Discovery of an orally efficacious imidazo[5,1-f][1,2,4]triazine dual inhibitor of IGF-1R and IR. ACS Med. Chem. Lett. 2010, 1, 510-515. Compound 9b in this manuscript is referred to FQIT (cis-3-[4-amino-5-(8-fluoro-2-phenyl-quinolin- 7-yl)-imidazo[5,1-f][1,2,4]triazin-7-yl]-1-methylcyclobutanol) herein.
37. WU, J., LI, W., CRADDOCK, B. P., FOREMAN, K. W., MULVIHILL, M. J., JI, Q. S., MILLER, W. T., and HUBBARD, S. R. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. Embo J. 2008, 27(14),1985-1994.
38. WERNER, D. S., DONG, H., KADALBAJOO, M., LAUFER, R.S., TAVARES-GRECO, P.A., VOLK, B.R., MULVIHILL, M. J., and CREW, A. P. Synthetic approaches to 5,7-disubstituted imidazo[5,1-f][1,2,4]triazin-4-amines. Tetrahedron Lett. 2010, 51, 3899-3901.
39. DRABER, W., TIMMLER, H., DICKORE, K., and DONNER, W. Liebigs Ann. Chem, 1976, 2206.
40. ARNOLD, L. D., CESARIO, C., COATE, H., CREW, A. P., DONG, H., FOREMAN, K., HONDA, A., LAUFER, R., LI, A., MULVIHILL, K. M., MULVIHILL, M. J., NIGRO, A., PANICKER, B., STEINIG, A. G., SUN, Y., WENG, Q., WERNER, D. S., WYLE, M. J., and ZHANG, T. Preparation of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. PCT Int. Appl. 2005, WO 2005097800.
41. BUCK, E., EYZAGUIRRE, A., ROSENFELD-FRANKLIN, M., BROWN, E., O'CONNOR. M., YAO, Y., PACHTER, J., MIGLARESE, M., EPSTEIN, D., IWATA, K., HALEY, J. D., GIBSON, N. W., and JI, Q. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68, 8322-8332.
42. 0=median tumor volume of the control group at time 0. Mean %TGI was calculated for the entire dosing period for each group. Significant antitumor activity is defined as mean %TGI > 50%.